Strides Pharma Science Ltd on Monday reported a 51 per cent rise in consolidated net profit at ₹129.28 crore for the fourth quarter ended March 31, 2026 driven by a good growth in its main markets excluding the US.
The company had posted a profit of ₹85.62 crore for the year-ago period, Strides Pharma said in a regulatory filing.
Revenue from operations in the quarter stood at ₹1,323.47 crore as compared to ₹1,190.39 crore in the year-ago period, it added.
In the fourth quarter, revenue from main markets excluding the US was up at ₹645.8 crore as compared to ₹480 crore in the year-ago period. The US market revenue was at ₹646.7 crore, down from ₹651.5 crore in the year-ago period, the company said in an investor presentation.
Total expenses in the quarter under review were higher at ₹1,178.59 crore as compared to ₹1,071.71 crore in the same period a year ago, the company said.
In FY26, consolidated net profit was at ₹574.52 crore as compared to ₹3,597.51 crore in FY25, which was boosted by a profit after tax from discontinued operations of ₹3,188.11 crore. Revenue from operations stood at ₹4,858.68 crore as against ₹4,565.34 crore.
Commenting on the performance, Strides Pharma Science MD & Group CEO Badree Komandur said the company continued to deliver strong performance across profitability, efficiency, and growth metrics during FY26, primarily driven by the Ex-US markets,
“Our calibrated strategy in Ex-US markets is delivering results, with these markets outpacing overall company growth. The US business remained stable during the year, though impacted by a weaker flu season in the second half,” he added.
Komandur further said,”Despite ongoing geopolitical uncertainties and a challenging external environment, we are committed to delivering long-term sustainable and profitable growth.”
The board of directors has recommended a final dividend of ₹5 per equity share of ₹10 each, at the rate of 50 per cent, for FY26, the company said.
